Global Peptide and Oligonucleotide Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Peptide and Oligonucleotide Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Peptide and Oligonucleotide Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oligonucleotide Drugs
1.2.3 Peptide Drugs
1.3 Market Segmentation by Application
1.3.1 Global Peptide and Oligonucleotide Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Immunomodulatory Drugs
1.3.3 Digestive system Drugs
1.3.4 Bone and Connective Tissue Types
1.3.5 Oncology Drugs
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Peptide and Oligonucleotide Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Peptide and Oligonucleotide Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Peptide and Oligonucleotide Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Peptide and Oligonucleotide Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Peptide and Oligonucleotide Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Peptide and Oligonucleotide Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Oligonucleotide Drugs Market Size by Manufacturers
3.5.2 Peptide Drugs Market Size by Manufacturers
3.6 Global Peptide and Oligonucleotide Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Peptide and Oligonucleotide Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Peptide and Oligonucleotide Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Peptide and Oligonucleotide Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Peptide and Oligonucleotide Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Peptide and Oligonucleotide Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Peptide and Oligonucleotide Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Peptide and Oligonucleotide Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Peptide and Oligonucleotide Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Peptide and Oligonucleotide Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Peptide and Oligonucleotide Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Peptide and Oligonucleotide Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Peptide and Oligonucleotide Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Peptide and Oligonucleotide Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Peptide and Oligonucleotide Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Peptide and Oligonucleotide Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Peptide and Oligonucleotide Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Peptide and Oligonucleotide Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Peptide and Oligonucleotide Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.1.4 Novartis Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Peptide and Oligonucleotide Drugs Sales by Product in 2024
11.1.6 Novartis Peptide and Oligonucleotide Drugs Sales by Application in 2024
11.1.7 Novartis Peptide and Oligonucleotide Drugs Sales by Geographic Area in 2024
11.1.8 Novartis Peptide and Oligonucleotide Drugs SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Ionis
11.2.1 Ionis Corporation Information
11.2.2 Ionis Business Overview
11.2.3 Ionis Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.2.4 Ionis Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Ionis Peptide and Oligonucleotide Drugs Sales by Product in 2024
11.2.6 Ionis Peptide and Oligonucleotide Drugs Sales by Application in 2024
11.2.7 Ionis Peptide and Oligonucleotide Drugs Sales by Geographic Area in 2024
11.2.8 Ionis Peptide and Oligonucleotide Drugs SWOT Analysis
11.2.9 Ionis Recent Developments
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Corporation Information
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.3.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales by Product in 2024
11.3.6 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales by Application in 2024
11.3.7 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales by Geographic Area in 2024
11.3.8 Nippon Shinyaku Peptide and Oligonucleotide Drugs SWOT Analysis
11.3.9 Nippon Shinyaku Recent Developments
11.4 Alnylam
11.4.1 Alnylam Corporation Information
11.4.2 Alnylam Business Overview
11.4.3 Alnylam Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.4.4 Alnylam Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Alnylam Peptide and Oligonucleotide Drugs Sales by Product in 2024
11.4.6 Alnylam Peptide and Oligonucleotide Drugs Sales by Application in 2024
11.4.7 Alnylam Peptide and Oligonucleotide Drugs Sales by Geographic Area in 2024
11.4.8 Alnylam Peptide and Oligonucleotide Drugs SWOT Analysis
11.4.9 Alnylam Recent Developments
11.5 Sarepta Therapeutics
11.5.1 Sarepta Therapeutics Corporation Information
11.5.2 Sarepta Therapeutics Business Overview
11.5.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.5.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales by Product in 2024
11.5.6 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales by Application in 2024
11.5.7 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales by Geographic Area in 2024
11.5.8 Sarepta Therapeutics Peptide and Oligonucleotide Drugs SWOT Analysis
11.5.9 Sarepta Therapeutics Recent Developments
11.6 MiNA Therapeutics
11.6.1 MiNA Therapeutics Corporation Information
11.6.2 MiNA Therapeutics Business Overview
11.6.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.6.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 MiNA Therapeutics Recent Developments
11.7 BioNTech
11.7.1 BioNTech Corporation Information
11.7.2 BioNTech Business Overview
11.7.3 BioNTech Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.7.4 BioNTech Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 BioNTech Recent Developments
11.8 Moderna
11.8.1 Moderna Corporation Information
11.8.2 Moderna Business Overview
11.8.3 Moderna Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.8.4 Moderna Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Moderna Recent Developments
11.9 Merck Serono
11.9.1 Merck Serono Corporation Information
11.9.2 Merck Serono Business Overview
11.9.3 Merck Serono Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.9.4 Merck Serono Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Merck Serono Recent Developments
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Corporation Information
11.10.2 Ferring Pharmaceuticals Business Overview
11.10.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.10.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Ferring Pharmaceuticals Recent Developments
11.11 Ipsen PHarma Biotech
11.11.1 Ipsen PHarma Biotech Corporation Information
11.11.2 Ipsen PHarma Biotech Business Overview
11.11.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.11.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Ipsen PHarma Biotech Recent Developments
11.12 Lilly
11.12.1 Lilly Corporation Information
11.12.2 Lilly Business Overview
11.12.3 Lilly Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.12.4 Lilly Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Lilly Recent Developments
11.13 Asahi Kasei
11.13.1 Asahi Kasei Corporation Information
11.13.2 Asahi Kasei Business Overview
11.13.3 Asahi Kasei Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.13.4 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Asahi Kasei Recent Developments
11.14 AstraZeneca
11.14.1 AstraZeneca Corporation Information
11.14.2 AstraZeneca Business Overview
11.14.3 AstraZeneca Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.14.4 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 AstraZeneca Recent Developments
11.15 SciClone Pharmaceuticals
11.15.1 SciClone Pharmaceuticals Corporation Information
11.15.2 SciClone Pharmaceuticals Business Overview
11.15.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.15.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 SciClone Pharmaceuticals Recent Developments
11.16 Takeda
11.16.1 Takeda Corporation Information
11.16.2 Takeda Business Overview
11.16.3 Takeda Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.16.4 Takeda Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Takeda Recent Developments
11.17 Roche
11.17.1 Roche Corporation Information
11.17.2 Roche Business Overview
11.17.3 Roche Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.17.4 Roche Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Roche Recent Developments
11.18 Sanofi
11.18.1 Sanofi Corporation Information
11.18.2 Sanofi Business Overview
11.18.3 Sanofi Peptide and Oligonucleotide Drugs Product Models, Descriptions and Specifications
11.18.4 Sanofi Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Sanofi Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Peptide and Oligonucleotide Drugs Industry Chain
12.2 Peptide and Oligonucleotide Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Peptide and Oligonucleotide Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Peptide and Oligonucleotide Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Peptide and Oligonucleotide Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Peptide and Oligonucleotide Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Peptide and Oligonucleotide Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Peptide and Oligonucleotide Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Peptide and Oligonucleotide Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Peptide and Oligonucleotide Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Peptide and Oligonucleotide Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Peptide and Oligonucleotide Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Peptide and Oligonucleotide Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Peptide and Oligonucleotide Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide Drugs as of 2024)
Table 16. Global Peptide and Oligonucleotide Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Peptide and Oligonucleotide Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Peptide and Oligonucleotide Drugs Manufacturing Base and Headquarters
Table 19. Global Peptide and Oligonucleotide Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Peptide and Oligonucleotide Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Peptide and Oligonucleotide Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Peptide and Oligonucleotide Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Peptide and Oligonucleotide Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Peptide and Oligonucleotide Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Peptide and Oligonucleotide Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Peptide and Oligonucleotide Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Peptide and Oligonucleotide Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Peptide and Oligonucleotide Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Peptide and Oligonucleotide Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Peptide and Oligonucleotide Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Peptide and Oligonucleotide Drugs Growth Accelerators and Market Barriers
Table 37. North America Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Peptide and Oligonucleotide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Peptide and Oligonucleotide Drugs Growth Accelerators and Market Barriers
Table 40. Europe Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Peptide and Oligonucleotide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Peptide and Oligonucleotide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Peptide and Oligonucleotide Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Peptide and Oligonucleotide Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Peptide and Oligonucleotide Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Novartis Corporation Information
Table 51. Novartis Description and Major Businesses
Table 52. Novartis Product Models, Descriptions and Specifications
Table 53. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Novartis Sales Value Proportion by Product in 2024
Table 55. Novartis Sales Value Proportion by Application in 2024
Table 56. Novartis Sales Value Proportion by Geographic Area in 2024
Table 57. Novartis Peptide and Oligonucleotide Drugs SWOT Analysis
Table 58. Novartis Recent Developments
Table 59. Ionis Corporation Information
Table 60. Ionis Description and Major Businesses
Table 61. Ionis Product Models, Descriptions and Specifications
Table 62. Ionis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Ionis Sales Value Proportion by Product in 2024
Table 64. Ionis Sales Value Proportion by Application in 2024
Table 65. Ionis Sales Value Proportion by Geographic Area in 2024
Table 66. Ionis Peptide and Oligonucleotide Drugs SWOT Analysis
Table 67. Ionis Recent Developments
Table 68. Nippon Shinyaku Corporation Information
Table 69. Nippon Shinyaku Description and Major Businesses
Table 70. Nippon Shinyaku Product Models, Descriptions and Specifications
Table 71. Nippon Shinyaku Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Nippon Shinyaku Sales Value Proportion by Product in 2024
Table 73. Nippon Shinyaku Sales Value Proportion by Application in 2024
Table 74. Nippon Shinyaku Sales Value Proportion by Geographic Area in 2024
Table 75. Nippon Shinyaku Peptide and Oligonucleotide Drugs SWOT Analysis
Table 76. Nippon Shinyaku Recent Developments
Table 77. Alnylam Corporation Information
Table 78. Alnylam Description and Major Businesses
Table 79. Alnylam Product Models, Descriptions and Specifications
Table 80. Alnylam Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Alnylam Sales Value Proportion by Product in 2024
Table 82. Alnylam Sales Value Proportion by Application in 2024
Table 83. Alnylam Sales Value Proportion by Geographic Area in 2024
Table 84. Alnylam Peptide and Oligonucleotide Drugs SWOT Analysis
Table 85. Alnylam Recent Developments
Table 86. Sarepta Therapeutics Corporation Information
Table 87. Sarepta Therapeutics Description and Major Businesses
Table 88. Sarepta Therapeutics Product Models, Descriptions and Specifications
Table 89. Sarepta Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sarepta Therapeutics Sales Value Proportion by Product in 2024
Table 91. Sarepta Therapeutics Sales Value Proportion by Application in 2024
Table 92. Sarepta Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 93. Sarepta Therapeutics Peptide and Oligonucleotide Drugs SWOT Analysis
Table 94. Sarepta Therapeutics Recent Developments
Table 95. MiNA Therapeutics Corporation Information
Table 96. MiNA Therapeutics Description and Major Businesses
Table 97. MiNA Therapeutics Product Models, Descriptions and Specifications
Table 98. MiNA Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. MiNA Therapeutics Recent Developments
Table 100. BioNTech Corporation Information
Table 101. BioNTech Description and Major Businesses
Table 102. BioNTech Product Models, Descriptions and Specifications
Table 103. BioNTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. BioNTech Recent Developments
Table 105. Moderna Corporation Information
Table 106. Moderna Description and Major Businesses
Table 107. Moderna Product Models, Descriptions and Specifications
Table 108. Moderna Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Moderna Recent Developments
Table 110. Merck Serono Corporation Information
Table 111. Merck Serono Description and Major Businesses
Table 112. Merck Serono Product Models, Descriptions and Specifications
Table 113. Merck Serono Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Merck Serono Recent Developments
Table 115. Ferring Pharmaceuticals Corporation Information
Table 116. Ferring Pharmaceuticals Description and Major Businesses
Table 117. Ferring Pharmaceuticals Product Models, Descriptions and Specifications
Table 118. Ferring Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Ferring Pharmaceuticals Recent Developments
Table 120. Ipsen PHarma Biotech Corporation Information
Table 121. Ipsen PHarma Biotech Description and Major Businesses
Table 122. Ipsen PHarma Biotech Product Models, Descriptions and Specifications
Table 123. Ipsen PHarma Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Ipsen PHarma Biotech Recent Developments
Table 125. Lilly Corporation Information
Table 126. Lilly Description and Major Businesses
Table 127. Lilly Product Models, Descriptions and Specifications
Table 128. Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Lilly Recent Developments
Table 130. Asahi Kasei Corporation Information
Table 131. Asahi Kasei Description and Major Businesses
Table 132. Asahi Kasei Product Models, Descriptions and Specifications
Table 133. Asahi Kasei Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Asahi Kasei Recent Developments
Table 135. AstraZeneca Corporation Information
Table 136. AstraZeneca Description and Major Businesses
Table 137. AstraZeneca Product Models, Descriptions and Specifications
Table 138. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. AstraZeneca Recent Developments
Table 140. SciClone Pharmaceuticals Corporation Information
Table 141. SciClone Pharmaceuticals Description and Major Businesses
Table 142. SciClone Pharmaceuticals Product Models, Descriptions and Specifications
Table 143. SciClone Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. SciClone Pharmaceuticals Recent Developments
Table 145. Takeda Corporation Information
Table 146. Takeda Description and Major Businesses
Table 147. Takeda Product Models, Descriptions and Specifications
Table 148. Takeda Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Takeda Recent Developments
Table 150. Roche Corporation Information
Table 151. Roche Description and Major Businesses
Table 152. Roche Product Models, Descriptions and Specifications
Table 153. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Roche Recent Developments
Table 155. Sanofi Corporation Information
Table 156. Sanofi Description and Major Businesses
Table 157. Sanofi Product Models, Descriptions and Specifications
Table 158. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Sanofi Recent Developments
Table 160. Key Raw Materials Distribution
Table 161. Raw Materials Key Suppliers
Table 162. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 163. Milestones in Production Technology Evolution
Table 164. Distributors List
Table 165. Market Trends and Market Evolution
Table 166. Market Drivers and Opportunities
Table 167. Market Challenges, Risks, and Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources


List of Figures
Figure 1. Peptide and Oligonucleotide Drugs Product Picture
Figure 2. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Oligonucleotide Drugs Product Picture
Figure 4. Peptide Drugs Product Picture
Figure 5. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Immunomodulatory Drugs
Figure 7. Digestive system Drugs
Figure 8. Bone and Connective Tissue Types
Figure 9. Oncology Drugs
Figure 10. Other
Figure 11. Peptide and Oligonucleotide Drugs Report Years Considered
Figure 12. Global Peptide and Oligonucleotide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global Peptide and Oligonucleotide Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global Peptide and Oligonucleotide Drugs Sales (2020-2031) & (K Units)
Figure 17. Global Peptide and Oligonucleotide Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Peptide and Oligonucleotide Drugs Sales Volume Market Share in 2024
Figure 20. Global Peptide and Oligonucleotide Drugs Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Oligonucleotide Drugs Revenue Market Share by Manufacturer in 2024
Figure 23. Peptide Drugs Revenue Market Share by Manufacturer in 2024
Figure 24. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2020-2031)
Figure 25. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2020-2031)
Figure 26. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2020-2031)
Figure 27. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2020-2031)
Figure 28. North America Peptide and Oligonucleotide Drugs Sales YoY (2020-2031) & (K Units)
Figure 29. North America Peptide and Oligonucleotide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) in 2024
Figure 31. North America Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Peptide and Oligonucleotide Drugs Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Peptide and Oligonucleotide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) in 2024
Figure 41. Europe Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. France Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Peptide and Oligonucleotide Drugs Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Peptide and Oligonucleotide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. India Peptide and Oligonucleotide Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Peptide and Oligonucleotide Drugs Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Peptide and Oligonucleotide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Peptide and Oligonucleotide Drugs Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Peptide and Oligonucleotide Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. Peptide and Oligonucleotide Drugs Industry Chain Mapping
Figure 83. Regional Peptide and Oligonucleotide Drugs Manufacturing Base Distribution (%)
Figure 84. Global Peptide and Oligonucleotide Drugs Production Market Share by Region (2020-2031)
Figure 85. Peptide and Oligonucleotide Drugs Production Process
Figure 86. Regional Peptide and Oligonucleotide Drugs Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit